Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Ke Pan
Assistant Professor
Melanoma Medical Oncology
https://orcid.org/0000-0002-0163-1045
h-index
2793
Citations
32
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2005
2021
Research activity per year
Overview
Fingerprint
Network
Research output
(71)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Ke Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Cytokine Induced Killer Cell
81%
Immunotherapy
74%
Dendritic Cell
72%
Overall Survival
42%
Hepatocellular Carcinoma Cell Line
42%
Carcinoma Cell
39%
T Cell
37%
Tumor Volume
33%
Cytokine
30%
Western Blot
28%
Interleukin 17
26%
Real-Time Polymerase Chain Reaction
25%
Dendritic Cell Vaccine
20%
Antineoplastic Activity
20%
Cytotoxic T Cell
18%
Squamous Cell
18%
Killer Cell
17%
Immunocompetent Cell
17%
Cell Lysate
17%
Colony Formation
17%
Survival Rate
16%
Stomach Mucosa
14%
Tumor Cell
13%
Prognostic Biomarker
13%
Tumor Suppressor Gene
13%
Quantitative Reverse Transcription Polymerase Chain Reaction
13%
Gastric Cancer Cell Line
13%
CD4
12%
Programmed Cell Death
12%
Mouse Model
12%
Cytotoxic T-Cell
12%
Monoclonal Antibody
11%
Natural Killer Cell
11%
Maturation
11%
Nude Mouse
11%
Downregulation
11%
Immunity
10%
Epitope
10%
Interferon Gamma
10%
CD25
10%
CD8
9%
Immunoregulation
9%
Immune Response
9%
Cancer Cell
9%
Protein Expression
9%
T Cell Receptor
8%
Regulatory T Cell
8%
Stem Cell
8%
Human Leukocyte Antigen
8%
MHC Class I
8%
Keyphrases
Hepatocellular Carcinoma
100%
Cytokine-induced Killer Cells
62%
Poor Prognosis
49%
Cellular Immunotherapy
35%
Hepatocellular Carcinoma Patients
29%
Gastric Adenocarcinoma
28%
Primary Hepatocellular Carcinoma
28%
Dendritic Cells
27%
Decreased Expression
26%
Overall Survival
21%
Tumor Suppressor
21%
Reduced Expression
19%
Recurrent Nasopharyngeal Carcinoma
18%
Clinical Significance
18%
Remnant Gastric Cancer
18%
Carbofuran
17%
Tolerogenic Dendritic Cells
17%
Annexin A3 (ANXA3)
17%
Antitumor Immune Response
17%
OK-432
17%
Gemcitabine Plus Cisplatin
17%
Cytokine-induced Killer
16%
Hepatocellular Carcinoma Cells
14%
Transfusion
14%
Tumor
13%
T Cells
13%
ING2
13%
Tumor-infiltrating Lymphocytes
13%
Gastric Cancer
12%
Cisplatin-based Chemotherapy
12%
Radiotherapy
12%
Nasopharyngeal Carcinoma
12%
Natural Killer Cells
11%
Cell Lysate
10%
Renal Carcinoma Cells
10%
Antitumor Activity
10%
Prognostic Role
10%
Gastric Carcinoma
10%
Immunohistochemical Staining
10%
Loss of Heterozygosity
10%
Chemotherapy
10%
Oncogene
9%
Tumorigenesis
9%
Cell-based
9%
Renal Cell Carcinoma
9%
Oncogenesis
9%
Prognosis Value
9%
Quantitative PCR
9%
Indoleamines
8%
Esophageal Squamous Cell Carcinoma
8%
Medicine and Dentistry
Hepatocellular Carcinoma
89%
Neoplasm
66%
Cytokine Induced Killer Cell
44%
Immunotherapy
34%
Abdominal Cancer
33%
Stomach Adenocarcinoma
27%
Dendritic Cell
26%
Nasopharynx Carcinoma
26%
Overall Survival
26%
Tumor Suppressor Protein
23%
Cisplatin
17%
Gemcitabine
17%
Chemotherapy
17%
Immune Response
17%
Carcinogenesis
17%
Western Blot
14%
Cytotoxic T-Cell
13%
Cytokine
13%
Radiation Therapy
11%
Prognostic Factor
11%
Disease Free Survival
10%
Kaplan Meier Method
10%
Messenger RNA
10%
Clinical Significance
9%
Proportional Hazards Model
9%
Hepatocellular Carcinoma Cell Line
9%
Familial Adenomatous Polyposis
8%
Adenomatous Polyposis Coli
8%
Retropharyngeal Lymph Nodes
8%
Transcription Elongation Factor
8%
Infusion
8%
Transcription Factor AP 2
8%
Tumor Infiltrating Lymphocyte
8%
Fine-Needle Aspiration
8%
Glycerophosphoinositol Inositolphosphodiesterase
8%
High Density Lipoprotein Cholesterol
8%
Indoleamine 2,3 Dioxygenase
8%
Cancer Stem Cell
8%
Melanoma Antigen
8%
Melanocyte
8%
Adjuvant Therapy
8%
Esophagus Carcinoma
8%
Clinical Trial
8%
Uroplakin 1a
8%
Killer Cell
8%
Radiofrequency Ablation
8%
CTLA-4
8%
Immunoglobulin Domain
8%
Kidney Cancer
8%
Germline Mutation
8%
